Cancer Biomarkers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Cancer Biomarkers Market is segmented By Disease (Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and Other Diseases), By Type, By Profiling Technology and Geography.

Cancer Biomarkers Market Snapshot

Cancer Biomarkers Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 13.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The cancer biomarkers market is expected to register a CAGR of nearly 13.1% during the forecast period. Certain factors that are driving the market growth include the increased incidence of cancer, globally, and higher acceptance of treatments for cancer in the developing regions, the paradigm shift in healthcare, from disease diagnosis to risk assessment or early diagnosis, and increasing usage of biomarkers in drug development.

According to the World Health Organization (WHO) 2018 report, cancer is the second leading cause of death worldwide and is responsible for an estimated 9.6 million deaths in the year 2018. Globally, about 1 in 6 deaths is due to cancer. About 70% of deaths from cancer occur in low- and middle-income countries. Additionally, the increased burden of several lifestyle disorders is also expected to drive the market, as biomarkers play a vital role in risk assessment, early diagnosis, and effective monitoring of treatment.

As data is being generated aggressively in the healthcare sector, a few developing countries have surpassed the lack of data, and it is likely to become so in the remaining countries as well. This augmentation of data is expected to provide the basis for any national policy on cancer. In turn, this factor may possibly lead to an increase in the percentage of people opting for cancer treatment. Thus, the increase in demand in the low- and middle-income countries is projected to boost the cancer biomarkers market.

Scope of the Report

As per scope of the report, Biomarkers are chemical, physical, or biological parameters, which can be used to indicate disease states. Oncology biomarkers offer high-speed, non-invasive cancer diagnoses, and enhance cancer detection and screening. The cancer biomarkers market is segmented by disease, type, profiling technology, and geography.

By Disease
Prostate Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Other Diseases
By Type
Protein Biomarkers
Genetic Biomarkers
Other Types
By Profiling Technology
OMICS Technology
Imaging Technology
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East & Africa
South Africa
Rest of Middle-East & Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Lung Cancer Segment is Expected to Hold a Major Market Share in the Cancer Biomarkers Market

Lung cancer is the second most common type of cancer and the leading cause of death worldwide (caused by any type of cancer) among men and women, as per the 2018 statistics published by the American Society of Clinical Oncology.

Lung cancer is caused by the uncontrolled growth of abnormal cells that multiply in one lung or both lungs. Although it can affect people who never smoked, people who smoke have the highest risk of lung cancer. The risk of lung cancer increases with the duration and number of cigarettes that the patient smoked. Other risk factors include occupational or environmental exposure to secondhand smoke, asbestos, certain metals, some organic chemicals, radiation, air pollution, and diesel exhaust.

The primary factors driving the growth of this segment is the rising prevalence and incidence of lung cancer. According to GLOBOCAN, in 2018, 2,093,876 new cases of lung cancer were reported, globally. Some of the biomarkers for lung cancer include CYFRA 21-1, Plasma Kallikrein (KLKB1), Serum Amyloid A (SAA), Haptoglobin β Chain (Hp β), Complement Component 9 (C9), Endoglin (CD105), Peroxiredoxin 1 (PRX1), and Pro-gastrin-releasing Peptide (proGRP).

Moreover, with such a high incidence rate of lung cancer across the world, the demand for diagnostic devices is sure to rise, in turn, leading to the growth of this segment in the years to come.

Cancer Biomarkers Market

North America Dominates the Market and is Expected to do the Same Over the Forecast Period

The United States witnessed a considerable rise in the number of cancer patients. According to the estimates of the American Cancer Society, in 2018, in the United States, 1,735,350 new cancer cases were diagnosed and 609,640 deaths occurred due to cancer. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.

The ease in the United States government regulations and availability of funds from various organizations, like the National Institute of Health, has provided the potential for researchers to invest more in the use of biomarkers in drug discovery, drug development, detection of specific tumours, monitoring biological response to cancer therapy, and genetic studies for the identification of predisposed candidates of cancer.

Cancer Biomarkers Market

Competitive Landscape

The cancer biomarkers market is highly competitive and consists of a few major players. Some of the companies which are currently dominating the market are 23andMe, Abbott Laboratories Inc., Agilent Technologies, Ambry Genetics, Biomerieux, Celera Corporation (Quest Diagnostics), F. Hoffmann-La Roche Ltd, Hologic Inc., Illumina Inc., and Thermo Fisher Scientific, among others, hold substantial shares in the market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increased Burden of Cancer, Globally, and Higher Acceptance for Treatment in the Developing Regions

      2. 4.2.2 Paradigm Shift in Healthcare from Disease Diagnosis to Risk Assessment or Early Diagnosis

      3. 4.2.3 Increasing Focus on Innovative Drug Development

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Diagnosis

      2. 4.3.2 Reimbursement Issues

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Disease

      1. 5.1.1 Prostate Cancer

      2. 5.1.2 Breast Cancer

      3. 5.1.3 Lung Cancer

      4. 5.1.4 Colorectal Cancer

      5. 5.1.5 Cervical Cancer

      6. 5.1.6 Other Diseases

    2. 5.2 By Type

      1. 5.2.1 Protein Biomarkers

      2. 5.2.2 Genetic Biomarkers

      3. 5.2.3 Other Types

    3. 5.3 By Profiling Technology

      1. 5.3.1 OMICS Technology

      2. 5.3.2 Imaging Technology

      3. 5.3.3 Immunoassays

      4. 5.3.4 Cytogenetics

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East & Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 23andMe

      2. 6.1.2 Abbott Laboratories Inc.

      3. 6.1.3 Agilent Technologies

      4. 6.1.4 Ambry Genetics (Konica Minolta Inc.)

      5. 6.1.5 Biomerieux

      6. 6.1.6 Quest Diagnostics

      7. 6.1.7 F. Hoffmann-La Roche Ltd

      8. 6.1.8 Hologic Inc.

      9. 6.1.9 Illumina Inc.

      10. 6.1.10 Thermo Fisher Scientific

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Cancer Biomarkers Market market is studied from 2018 - 2026.

The Cancer Biomarkers Market is growing at a CAGR of 13.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Abbott Laboratories Inc., Thermo Fisher Scientific, Biomerieux, Illumina Inc., F. Hoffmann-La Roche Ltd are the major companies operating in Cancer Biomarkers Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!